The clinical hold doesn’t cover its drug’s Investigational New Drug application for autoimmune hepatitis, for which the Phase ...

The FDA has placed Kezar Life Sciences’ lupus trial on hold after the biotech flagged four deaths during the phase 2b study.

The company had voluntary suspended subject enrolment and dosing in the Phase II PALIZADE trial of zetomipzomib.

Kezar was testing the drug in patients with active lupus nephritis, which causes inflammation ... of the fatalities showed a common pattern of symptoms and the deaths happened close to the time ...

There are a number of symptoms of multiple sclerosis (MS) that may affect women, experts have said. The UK health body explained: "Symptoms may come (called "flare-ups" or "relapses") and go ...

Panelists discuss the goals of therapy for lupus nephritis (LN), emphasizing the urgency of treatment to prevent renal flares and the consequences of untreated LN, as well as strategies for ...

Panelists discuss the updated treatment recommendations for lupus nephritis in the Kidney Disease Improving Global Outcomes and European Alliance of Associations for Rheumatology guidelines ...

“Not only for myself but for my family and for other little girls ... when they’re diagnosed and that the condition requires more aggressive treatment than for symptoms like mild joint pain. Wants to ...

(Reuters) -The U.S. Food and Drug Administration has placed a clinical hold on Kezar Life Sciences' trial of experimental drug for lupus, the company said on Friday. The FDA's decision comes after the ...

Lupkynis (voclosporin) is now approved in Japan to treat lupus nephritis, a complication of lupus marked by kidney damage and inflammation. The Japanese Ministry of Health, Labour, and Welfare ...